

# Clopidogrel, aspirin and rivaroxaban after a medical procedure used to widen narrowed or blocked arteries using a balloon or stent

<b>Submission date</b> 28/06/2024	<b>Recruitment status</b> Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 22/08/2024	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 22/01/2025	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Blocked leg arteries, often caused by diabetes or smoking, are increasingly common and can result in potentially severe consequences like amputation or even death if left untreated. In the UK, between 16,500 and 30,000 people die and 3,500 face amputations due to heavily blocked leg arteries annually. Each year, over 4,000 angioplasty medical procedures are conducted in the UK to widen narrowed or blocked arteries using a balloon or stent. After an angioplasty, patients typically receive medications known as “blood thinners” to prevent blood clots and lower the chance of needing an amputation. Despite the widespread use of various tablet combinations by vascular surgeons in the UK, the optimal blood thinners for effectiveness and safety remain unknown.

This research will compare three commonly used blood thinners after angioplasty: Clopidogrel alone, Aspirin and Clopidogrel, and Aspirin and Rivaroxaban. The research will be ‘randomised’, meaning that patients will be randomly chosen by a computer to receive one of the three treatments, ensuring equal chances for each. Everything else will be the same.

The research aims to determine the optimal blood thinners for preventing complications of blocked arteries after angioplasty without causing too much bleeding. The research will also assess how much value these treatments provide in terms of their cost for the National Health Service (NHS). The results are expected to help improve the care of many patients needing angioplasty in the future.

### Who can participate?

This research will involve roughly 20 vascular units in the UK, with 1,239 participants undergoing angioplasty in the lower leg due to blocked arteries.

### What does the study involve?

Within 10 days of angioplasty, participants will start taking the assigned blood thinners for up to three years. We will ask participants about their quality of life and will be monitored for health problems such as further blockages, amputations, heart attacks, strokes and serious bleeding.

What are the possible benefits and risks of participating?

Benefits:

By participating in this trial, you will be helping us to answer questions about the optimal blood-thinners after angioplasty in the lower leg that may result in better care for patients needing this in the future. We know patients who are enrolled in randomised trials tend to do better medically than those who are not, probably because they have more points of contact with the hospital.

Risks:

The major burden on participants is the time taken to complete pain and quality of life questionnaires at baseline and 2, 6 and 12 months and possibly at 24 and 36 months after their procedure. While there are potential risks to taking the medicinal products, the risk is no higher than the risk of standard medical care. These medicines will be used within the licensed range of indications, dosage and form, and are all and are all currently used in UK clinical practice to all patients after endovascular intervention to reduce the risk of subsequent ischaemic events such as acute limb ischemia or myocardial infarction outside of the trial. The known and most commonly anticipated safety issue is bleeding risk. To minimise risks, patients at risk of increased bleeding will be excluded. E.g. patients with pre-existing indication for dual antiplatelet therapy or anticoagulant (atrial fibrillation and inherited and acquired bleeding disorders), open bypass as part of hybrid procedure, , active malignancy or any other non-vascular condition associated with a life expectancy of less than 36 months, embolic arterial disease, non-atherosclerotic Peripheral Arterial Disease (PAD), renal failure with creatinine clearance <15ml/minute.

Some patients have arterial disease in more than one territory (e.g. peripheral arterial disease and coronary artery disease; polyvascular disease) and are known to be at higher risk of both ischaemic and bleeding events. The bleeding risk of some patients with polyvascular disease will exclude them from CLARITY PAD.

Patients taking anticoagulants are to be carefully observed for signs of bleeding. Major bleeding is our primary safety outcome and other bleeding outcomes will be followed up as secondary outcome measures. The anticipated safety issues will be addressed within normal clinical practice.

Patients will be monitored for signs of bleeding and treatment should be stopped if severe bleeding occurs. In addition to restrictive eligibility criteria, other risk mitigation strategies include trial oversight from the Trial Management Group (TMG), Independent Data Monitoring Committee (IDMC) and Trial Steering Committee (TSC).

Where is the study run from?

Cardiff University (UK)

When is the study starting and how long is it expected to run for?

June 2024 to December 2028

Who is funding the study?

National Institute for Health and Care Research (NIHR) (UK).

Who is the main contact?

Clarity-Trial@cardiff.ac.uk

**Study website**

<https://www.claritypadtrial.co.uk>

# Contact information

## Type(s)

Scientific

## Contact name

Dr Wakunyambo Maboshe

## Contact details

Centre for Trials Research, 7th Floor, Neuadd Meirionnydd, Heath Park  
Cardiff  
United Kingdom  
CF14 4YS  
+44 29 20687457  
maboshew1@cardiff.ac.uk

## Type(s)

Scientific, Principal Investigator

## Contact name

Mr Christopher Twine

## Contact details

Southmead Hospital, Southmead Road, Westbury-on-Trym  
Bristol  
United Kingdom  
BS10 5NB  
+44 1174 4140826  
christopher.twine@bristol.ac.uk

# Additional identifiers

## EudraCT/CTIS number

Nil known

## IRAS number

1007268

## ClinicalTrials.gov number

Nil known

## Secondary identifying numbers

R&D 5410, IRAS 1007268

# Study information

## Scientific Title

Clopidogrel, Aspirin and Rivaroxaban after revascularisation with angioplasty for limb-threatening Peripheral Arterial Disease (CLARITY PAD)

## **Acronym**

CLARITY PAD

## **Study objectives**

Primary objective:

To compare the clinical effectiveness of three commonly used antithrombotic regimens (clopidogrel; aspirin plus clopidogrel; aspirin plus low-dose rivaroxaban) following endovascular intervention for CLTI

Secondary objectives:

1. To evaluate the effect of three commonly used antithrombotic regimens on major adverse limb events, major adverse cardiovascular events, major bleeding, minor bleeding, primary and secondary patency of artery, reintervention, healing of tissue loss, health-related quality of life, resource use and costs.
2. To evaluate the delivery of the CLARITY trial and trial interventions through qualitative process evaluation

## **Ethics approval required**

Ethics approval required

## **Ethics approval(s)**

Approved 21/08/2024, Wales REC 5 (Castlebridge 4, 15-19 Cowbridge Rd E, Cardiff, CF11 9AB, United Kingdom; +44 2921 052459; Wales.REC5@Wales.nhs.uk), ref: 24/WA/0211

## **Study design**

Pragmatic adaptive multicentre open-label three-arm individually randomized controlled trial

## **Primary study design**

Interventional

## **Secondary study design**

Randomised controlled trial

## **Study setting(s)**

Hospital

## **Study type(s)**

Safety, Efficacy

## **Participant information sheet**

Not available in web format, please use contact details to request a participant information sheet

## **Health condition(s) or problem(s) studied**

Antithrombotic treatment after percutaneous or hybrid endovascular intervention for chronic limb-threatening ischemia of the lower limbs

## **Interventions**

Oral course (up to 36 months) of one of the following treatments:

1. A 75mg clopidogrel tablet taken once daily

2. Dual antiplatelet therapy with a 75mg aspirin tablet and 75mg clopidogrel tablet, both taken once daily
3. Dual antiplatelet therapy with a 75mg aspirin tablet taken once daily and a 2.5mg rivaroxaban tablet taken twice daily

Participants in all trial arms will be followed up within 2-months of the procedure, at 6 months and annually post-procedure.

Treatment and follow-up duration will range between 1 year and 3 years depending on when the participant joins the trial.

## **Intervention Type**

Drug

## **Pharmaceutical study type(s)**

Pharmacoeconomic, Therapy, Others (A qualitative process evaluation study of 10-20 health professionals and 20-30 patients and a qualitative study within a trial (SWAT) of 10-20 patients and participating clinicians (n=10-20) to understand how to better recruit patients with higher risk of bleeding and often excluded from randomised controlled trials for future research.)

## **Phase**

Phase IV

## **Drug/device/biological/vaccine name(s)**

Aspirin, clopidogrel besilate, rivaroxaban

## **Primary outcome measure**

A composite event-free survival time of:

1. Acute limb ischaemia
2. Major lower limb amputation
3. Myocardial infarction
4. Ischaemic stroke
5. All-cause mortality

Measured using patient records at 2 months, 6 months, 12 months, 24 months and 36 months

## **Secondary outcome measures**

Measured via case report forms (CRFs) or questionnaires either from patient notes or directly from participants at 2 months, 6 months, 12 months, 24 months and 36 months:

1. Major adverse limb events (MALE) (defined as amputation or major reintervention of the trial limb)
2. Major adverse cardiovascular events (MACE) (defined as recurrent CLTI, amputation affecting contralateral limb, acute coronary syndrome, ischaemic stroke)
3. Bleeding Academic Research Consortium (BARC 2, 3 or 5) and Thrombolysis In Myocardial Infarction (TIMI) defined major bleeding
4. Minor bleeding
5. Primary and secondary patency of artery
6. Reintervention
7. Healing of tissue loss
8. Health-related quality of life (VasculQoL and EQ-5D-5L)
9. Cost-effectiveness
10. Qualitative process evaluation

**Overall study start date**

02/01/2024

**Completion date**

31/12/2028

## Eligibility

**Key inclusion criteria**

1. Adults (aged 18 years and over) undergoing percutaneous or hybrid endovascular intervention for CLTI of the lower limbs
2. Atherosclerosis as the cause of CLTI
3. Target arteries: infrainguinal (common femoral to pedal) if percutaneous, or iliac to pedal if performed as part of hybrid revascularisation with common femoral endarterectomy
4. Clinicians would use trial antithrombotic combinations in normal clinical practice
5. Able to provide informed consent
6. First time in the CLARITY trial

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Both

**Target number of participants**

1,239

**Key exclusion criteria**

1. Open lower-limb bypass as part of hybrid procedure
2. Pre-existing clinical indication for dual antiplatelet therapy or anticoagulant e.g. atrial fibrillation
3. Active malignancy or any other non-vascular condition associated with a life expectancy of less than 36 months
4. Patients undergoing intervention to treat asymptomatic restenosis of a lower-limb bypass graft
5. Embolic arterial disease
6. Renal failure with creatinine clearance  $<15\text{ml/minute}$
7. Thrombophilia or any other inherited or acquired bleeding disorders
8. Persons of childbearing potential who have a positive pregnancy test, are breastfeeding or attempting pregnancy

**Date of first enrolment**

14/01/2025

**Date of final enrolment**

30/06/2027

## **Locations**

**Countries of recruitment**

England

United Kingdom

Wales

**Study participating centre****Southmead Hospital**

Southmead Road

Westbury-on-trym

Bristol

United Kingdom

BS10 5NB

**Study participating centre****University Hospital of Wales**

Heath Park

Cardiff

United Kingdom

CF14 4XW

**Study participating centre****St Thomas' Hospital**

Westminster Bridge Road

London

United Kingdom

SE1 7EH

**Study participating centre****St Georges University Hospital**

Blackshaw Road

London

United Kingdom

SW17 0QT

**Study participating centre****Leeds General Infirmary**

Great George Street  
Leeds  
United Kingdom  
LS1 3EX

**Study participating centre****Hull Royal Infirmary**

Anlaby Road  
Hull  
United Kingdom  
HU3 2JZ

**Study participating centre****St Marys Hospital**

St. Marys Hospital  
Floyd Drive  
Warrington  
United Kingdom  
WA2 8DB

**Study participating centre****Northern General Hospital**

Northern General Hospital NHS Trust  
C Floor, Huntsmnan Building  
Herries Road  
Sheffield  
United Kingdom  
S5 7AU

**Study participating centre****Addenbrookes**

Addenbrookes Hospital  
Hills Road  
Cambridge  
United Kingdom  
CB2 0QQ

**Sponsor information**



**Organisation**

North Bristol NHS Trust

**Sponsor details**

Level 3, Learning & Research building

Southmead Hospital

Westbury on Trym

Bristol

England

United Kingdom

BS10 5NB

-

researchsponsor@nbt.nhs.uk

**Sponsor type**

University/education

**Website**

<http://www.nbt.nhs.uk/>

**ROR**

<https://ror.org/036x6gt55>

**Funder(s)****Funder type**

Government

**Funder Name**

Health Technology Assessment Programme

**Alternative Name(s)**

NIHR Health Technology Assessment Programme, HTA

**Funding Body Type**

Government organisation

**Funding Body Subtype**

National government

**Location**

United Kingdom

**Results and Publications**

**Publication and dissemination plan**

The findings will be presented at medical conferences, published in free to access medical journals, and shared with people who write peripheral arterial disease (PAD) guidelines and policies. We will share results via the national press, relevant charities and social media.

**Intention to publish date**

30/06/2029

**Individual participant data (IPD) sharing plan**

The current data sharing plans for this study are unknown and will be available at a later date.

**IPD sharing plan summary**

Data sharing statement to be made available at a later date